-- 獨立研究機構CFRA向提供了以下研究報告。 CFRA分析師總結如下：ICLR股價在會計調查結束後上漲，2023-2024財年的營收虛報率低於先前預期的2%，2025年第三季的營收虛報率甚至更低。公司將重述所有受影響期間的財務業績，預計在第二季末之前發布年度報告。鑑於長期存在的負面因素消除，以及避免了包括客戶損失、詐欺或2023-2024財年收入虛報超過2%在內的最壞情況，我們認為今天的上漲是合理的。管理層評論表明，製藥/生技融資環境和專案取消趨勢可能會有所改善，而這些趨勢近期一直對公司構成不利影響。雖然我們預計ICLR將逐步恢復投資者信心，但我們認為，對於該公司以及生命科學工具和服務子行業的同行而言，營運環境仍然充滿挑戰。鑑於近期缺乏財務指引，我們認為前景仍然不明朗，並等待更新的財務數據以獲得更多證據來證明所提出的改進措施。
Related Articles
Australia
General Motors Could Top 2026 Outlook if Economy Stabilizes, UBS Says
General Motors (GM) could beat its 2026 outlook if the economy steadies, with further earnings growth likely into 2027 from cost control, electric vehicle profitability, stronger vehicle mix, and share buybacks, UBS said in a note emailed Wednesday.Investor concerns over commodity costs and demand risk misses General Motors' stronger execution, flexibility and spending control, according to the note.General Motors' outlook has some elements of conservatism because the company has not included a possible restocking of high-profit pickups and SUVs in its guidance, UBS said.The firm noted that possible USMCA trade talks are more likely to help the company than hurt it, though not included in its outlook.UBS kept its buy rating on General Motors and lowered its price target to $102 from $105.Price: $76.08, Change: $-2.87, Percent Change: -3.63%
$GM
Research
CGI Keeps Outperform Rating, C$150 Target at National Bank, Citing "Compelling Value", In-Line Q2 Results and "Light(er) Booking"
Price: $90.23, Change: $-10.41, Percent Change: -10.34%
$GIB-A.TO
Oil & Energy